| Previous Close | 1.59 |
| Open | 1.6 |
| Day High | 1.68 |
| Day Low | 1.57 |
| 52-Week High | 3.82 |
| 52-Week Low | 0.56 |
| Volume | 1.44M |
| Average Volume | 842,269 |
| Market Cap | 26.37M |
| PE | -2.88 |
| EPS | -0.58 |
| Moving Average 50 Days | 1.73 |
| Moving Average 200 Days | 1.74 |
| Change | 0.08 |
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
GlobeNewswire Inc.
Mar 09, 2026 11:00 AM GMT
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie dietSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator developing therapi
iBio to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Feb 24, 2026 12:00 PM GMT
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer, and Felipe Duran,
iBio Announces $26 Million Private Placement
GlobeNewswire Inc.
Jan 09, 2026 12:00 PM GMT
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing healthcare-focused, high-quality i